What if a medicine changes your eating in ways you do not know how to describe? You may feel relief from constant thoughts about food. You may also feel sick when you try to eat, become more afraid of food, or notice old rules returning. Those experiences need different questions, even when they happen while taking the same medicine.
Medicines that act on glucagon-like peptide-1, or GLP-1, have approved medical uses. But a benefit for one condition does not prove that a drug treats an eating disorder. It also does not tell us how it affects someone who is restricting food. If you are thinking about one of these drugs, or already take one, tell the prescriber about your eating history.12
The product and the reason for treatment matter
A GLP-1 receptor agonist acts on the pathway for that hormone. This pathway helps control appetite and other body functions. Tirzepatide acts on it and a second hormone pathway: glucose-dependent insulinotropic polypeptide, or GIP. People often group these drugs together. Yet their names, forms, approved uses, and age groups differ. Approval to treat diabetes does not carry over to a weight-management product or an eating-disorder use.23
As of September 2026, Wegovy injection has weight-management uses for adults and for children aged 12 and older who meet its label criteria. Wegovy tablets have approved uses in adults. Zepbound contains tirzepatide and has adult uses for weight management and obstructive sleep apnea. Mounjaro also contains tirzepatide. Its diabetes approval covers adults and children aged 10 and older who meet its label criteria, and it has a separate adult-only use for lowering heart risk. Each product has its own rules for who may receive it.234
A newer GLP-1 drug taken by mouth is orforglipron, sold as Foundayo. It received U.S. approval in April 2026 for weight management in adults who meet its label criteria. None of the labels reviewed here approves a drug to treat an eating disorder. More approved uses for other health needs do not mean more proven eating-disorder treatments.2345
If a clinician suggests an off-label use, ask what condition they aim to treat and what change they hope to see. Off-label means the U.S. Food and Drug Administration, or FDA, has not approved that use. This alone does not tell you whether it is a sound choice. The clinician must weigh the evidence, risks, other options, and your health needs.
What the BED studies actually show
Early studies in adults with binge-eating disorder, or BED, have raised a useful question: could these drugs reduce binge symptoms? They have not yet given a firm answer that applies across patients.
In 2026, researchers pooled 25 randomized trials with about 8,000 people. Most of those trials were not limited to people with a diagnosed eating disorder. On average, people taking these drugs reported fewer binge and loss-of-control episodes. They also reported holding back from food more. The researchers said it is not clear whether that holding back is healthy or harmful, and they rated every study as having a high risk of bias or some concerns about bias. They called for better trials in people diagnosed with BED.13
A small trial randomly assigned adults with BED to liraglutide or a placebo, which had no active drug. Binges declined in both groups. The difference between groups did not prove a benefit on the main binge measure. Weight change favored liraglutide. An error in giving out the study drugs and missing follow-up data further limit what we can learn. The weight and eating-disorder results answer different questions.6
A study that looked back at semaglutide treatment found better scores on a binge-eating survey. It did not assign treatment by chance. A better survey score is not the same as an interview confirming remission from the eating disorder. Differences among the people in each treatment group could help explain the result. The study supports further research. It cannot show that semaglutide works better than established BED care.7
These findings should not replace therapy focused on the eating disorder. They also should not replace a careful review of drugs approved for adult BED. The BED essay and medication essay explain those options.
A different history asks a different question
The evidence does not give one answer for everyone who has trouble eating. One condition below is avoidant/restrictive food intake disorder, or ARFID. Consider the questions a clinician may need to separate:
| Eating history | What remains important to assess |
|---|---|
| Active BED | Whether loss of control and distress improve, alongside nutrition, side effects, and daily life. |
| Anorexia or atypical anorexia | Whether restriction, fear, or nutritional harm is active or worsening. BED studies cannot establish safety here. |
| Bulimia | Binge and compensatory patterns, fluid balance, and medical risk. Less appetite does not establish recovery. |
| ARFID | Whether sensory limits, fear of eating, or low interest already make adequate intake hard. |
| A past eating disorder | Current symptoms, signs of recurrence, supports, and who will review changes. |
| No known eating disorder | Whether an unrecognized pattern is present, and whether new eating problems have started since treatment began, while preserving the medical reason for treatment.15 |
Use this table to support a discussion. It is not a screening tool or a decision to prescribe. We have little direct evidence for bulimia, ARFID, restrictive disorders, or a past eating disorder now in remission. Studies in adults also cannot prove safety or benefit in teens.16
A case report described worsening atypical anorexia in a teen using semaglutide. One case cannot show how often this happens or prove that the drug caused it. It does show why food restriction needs attention, even when weight-related treatment seemed to fit at first. The atypical anorexia essay explains why body size cannot settle medical risk.8
“Food noise” needs a clearer description
People use “food noise” to mean different things. You may mean unwanted thoughts that disrupt work. Someone else may mean hunger, cravings, worry about breaking a food rule, or urges to binge. The phrase alone does not tell the clinician what changed.
Try describing the change in ordinary terms. Are you less distressed and more able to eat with others? Are you avoiding meals because eating brings nausea? Do you feel pleased that eating has become harder, even while your energy or concentration worsens? Is an old fear of weight gain starting to direct more of your day?
These are different clinical questions. Lower appetite may occur with less binge distress, too little food, or stricter food rules. The team needs to assess your health and daily life as well as your thoughts about food. A joint advisory from several health groups calls for a review of eating history and nutrition needs before and during GLP-1 treatment.1
Less appetite does not prove an eating disorder. Stomach or gut side effects, another illness, lack of food access, and eating symptoms may overlap. Your clinician needs to know the pattern and when it began to work out what is happening.12
What screening can and cannot do
Before prescribing, a clinician can ask about past treatment, food restriction, loss of control, and attempts to undo eating. They can ask whether fear or sensory needs limit what you eat. The review should also cover whether you can meet nutrition needs, other drugs that affect appetite, and your sources of support. A brief negative screen cannot settle all of these questions.1
As of September 2026 there is no validated eating-disorder screen built for GLP-1 use and endorsed across the field. Validated means a tool has been tested to see how well it does its job. Existing screens can support an assessment, but they do not replace a talk with a clinician. Questions built around a stereotype may miss what a person is going through.
The 2025 nutrition advisory calls restrictive eating disorders a general contraindication, or reason not to use the drugs. This is expert advice. It is not a blanket FDA contraindication for every eating disorder. Each drug label has its own formal contraindications and warnings. A clinician should explain which source guides the decision.1235
If you have diabetes or another condition that benefits from treatment, those needs still matter. Eating-disorder risk does not erase them. Your team may include the prescriber, an eating-disorder clinician, and a dietitian who can assess nutrition. Ask who will review eating changes and how the team will respond to concerns.
A major safety update needs its own boundary
In January 2026, the FDA asked for warnings about suicidal thoughts and behavior to be removed from certain GLP-1 drug labels. It reviewed data from trials and health records and did not find a higher risk of these outcomes. An older warning does not reflect the FDA’s current finding.9
That finding does not prove safety in active anorexia, bulimia, or ARFID. The FDA review did not answer every eating-disorder question or rule out worsening nutrition. A reassuring result on one safety measure is not a general all-clear. New or worsening mental-health symptoms still deserve care.
Label warnings include severe stomach or gut effects and kidney problems linked to dehydration. These risks can make reduced intake a medical concern. Warnings vary by product. Your prescriber should review your symptoms, other drugs, and health history. A general claim about the whole drug class cannot replace that review.235
Unapproved products raise other questions about quality, safety, and what was supplied. The FDA warns that they do not receive the same review as approved drugs before being sold. Some people get these drugs online without ever talking to a clinician who knows their history. A 2026 U.S. survey found that people who screened positive for an eating disorder were more likely to have tried that route.14 Tell the clinician which product you have and where you got it. They need this information for your care. It should not keep you from asking for help.10
If you recognize yourself while taking a medicine
You do not need to decide alone whether the drug helps, causes harm, or has no link to the change. This article gives no blanket instruction to continue or stop it. Contact the prescriber promptly and describe what has happened, even if you have not had an eating-disorder diagnosis.
A note you can send is:
“Since starting treatment, my eating and thoughts about food have changed. I have noticed [describe the change], and it affects [daily life or physical symptoms]. My past eating history may matter. Can we review this together and coordinate eating-disorder assessment if needed?”
This week, send the note or arrange a review. Include the product name, other medicines, eating-disorder history, and current symptoms. You do not need to collect body measurements or test a different dose first. The neurodivergence essay may help you describe sensory needs or trouble with routines.
Seek emergency medical care for fainting or collapse, chest pain, trouble breathing, a heartbeat that feels fast, pounding, or irregular, a seizure, severe confusion, or vomiting blood. Severe dehydration, including being unable to keep fluids down, and passing very little urine also need emergency care. A long period of food restriction needs prompt assessment, too. Restoring nutrition may need medical supervision. These signs are examples, not a complete test of safety.11
In the United States, call 911 for an emergency or immediate danger. Call or text 988 for a suicidal or mental-health crisis. 988 does not replace emergency medical care. It is part of good care to ask how a drug affects your eating, even when it also meets a real health need.12
This article is for education and does not replace care from your own health professional. Eating disorders can affect people at any body size. If you are concerned about eating, exercise, or related symptoms, ask for an assessment. Do not start, stop, or change medication based on this article.
This article is for education only. It does not recommend for or against any GLP-1 medicine, does not tell you to start, stop, or change a prescription, does not state a dose, and does not substitute for the conversation with your own prescriber. It does not diagnose an eating disorder or set a target weight. Drug labeling changes; the labels cited here were current on September 7, 2026. Reading it does not create a clinician-patient relationship.
Eating disorder support and referrals
These are specialized eating disorder helplines, not 24/7 crisis lines. For urgent help any time, use the crisis resources below.
- National Alliance for Eating Disorders Helpline, 1-866-662-1235, Monday to Friday, 6 a.m. to 4 p.m. Pacific (9 a.m. to 7 p.m. Eastern). Staffed by licensed therapists who specialize in eating disorders; free referrals to all levels of care. allianceforeatingdisorders.com
- ANAD Helpline, 1-888-375-7767, Monday to Friday, 7 a.m. to 7 p.m. Pacific (9 a.m. to 9 p.m. Central). Peer support and treatment referrals.
- F.E.A.S.T., feast-ed.org. Free caregiver resources, online support groups, and family guides for those supporting a loved one with an eating disorder.
If you or your loved one has chest pain, fainting, seizures, severe weakness, confusion, signs of refeeding syndrome, or any other life-threatening symptom, call 911 or go to the nearest emergency room. Eating disorders are medical illnesses, and medical emergencies are common.
Related reading on NP FADY
- Binge Eating Is Not a Willpower Problem
- What Medication Can and Cannot Do
- You Can Be Very Sick at Any Weight
References
1. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. 2025;33(8):1475-1503. DOI: 10.1002/oby.24336. Corrigendum: Obesity. 2026;34(7):1516. DOI: 10.1002/oby.70222. https://onlinelibrary.wiley.com/doi/10.1002/oby.24336. Accessed September 7, 2026.
2. FDA. WEGOVY injection and tablets prescribing information. June 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf. Accessed September 7, 2026.
3. ZEPBOUND (tirzepatide) prescribing information. U.S. label revised August 2026. https://pi.lilly.com/us/zepbound-uspi.pdf. Accessed September 7, 2026.
4. MOUNJARO (tirzepatide) prescribing information. U.S. label revised August 2026. https://pi.lilly.com/us/mounjaro-uspi.pdf. Accessed September 7, 2026.
5. FOUNDAYO (orforglipron) prescribing information. U.S. label revised July 2026; original approval April 1, 2026 under NDA 220934. https://pi.lilly.com/us/foundayo-uspi.pdf. Accessed September 7, 2026.
6. Allison KC et al. A pilot randomized controlled trial of liraglutide 3.0 mg for BED. 2023; online 2022. DOI: 10.1002/osp4.619. https://onlinelibrary.wiley.com/doi/full/10.1002/osp4.619. Accessed September 7, 2026.
7. Richards J et al. Successful treatment of BED with semaglutide: a retrospective cohort study. 2023. DOI: 10.1016/j.obpill.2023.100080. https://pubmed.ncbi.nlm.nih.gov/37990682/. Accessed September 7, 2026.
8. Liekens L et al. Semaglutide-associated worsening of atypical anorexia nervosa in an adolescent girl: case report. 2026; online 2025. DOI: 10.1192/bjo.2025.10909. https://www.cambridge.org/core/journals/bjpsych-open/article/semaglutideassociated-worsening-of-atypical-anorexia-nervosa-in-an-adolescent-girl-case-report/E2356EAD3C2C97F20FFB085F67641C8E. Accessed September 7, 2026.
9. FDA. Requests removal of suicidal behavior and ideation warning from GLP-1 medications. January 13, 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp. Accessed September 7, 2026.
10. FDA. Concerns with unapproved GLP-1 drugs used for weight loss. Current communication checked September 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss. Accessed September 7, 2026.
11. Royal College of Psychiatrists. MEED, CR233. 2022; updated December 2025. https://www.rcpsych.ac.uk/improving-care/campaigning-for-better-mental-health-policy/college-reports/2022-college-reports/cr233. Accessed September 7, 2026.
12. 988 Suicide & Crisis Lifeline. Current U.S. service information. https://988lifeline.org/. Accessed September 7, 2026.
13. Emptage I, Kozmér S, Cobham-Wilson A, et al. The effectiveness of glucagon-like peptide-1 receptor agonists on binge eating in patients with obesity: a systematic review and meta-analysis. eClinicalMedicine. 2026;98:104007. Twenty-five randomized trials, 8,069 participants; all rated high risk of bias or some concerns. DOI: 10.1016/j.eclinm.2026.104007. PMID: 42666688. https://doi.org/10.1016/j.eclinm.2026.104007. Accessed September 7, 2026.
14. Siegel JA, Mumford EA, Kresovich A, Emery S, Jones C. Eating disorder screen results and GLP-1 awareness, interest, and use in a nationally representative sample of adults in U.S. households. Int J Eat Disord. 2026; online June 19, 2026. Cross-sectional survey, n=1,309. DOI: 10.1002/eat.70103. https://doi.org/10.1002/eat.70103. Accessed September 7, 2026.
15. Herb Neff KM, Dunford A, Goldschmidt AB, Allison KC, Richeson A. Eating disorder risk and screening in patients using GLP-1RAs: lessons learned from metabolic and bariatric surgery. Int J Eat Disord. 2026; online July 26, 2026. DOI: 10.1002/eat.70180. PMID: 42502918. https://doi.org/10.1002/eat.70180. Accessed September 7, 2026.
If you or someone you know is in crisis
- Call 911 or go to your nearest emergency room for any life-threatening emergency.
- 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
- Crisis Text Line — text HOME to 741741.
- The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
- National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
- National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
- Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
- San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
- Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
- California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
- NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.